Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

5.715 +0.085 (+1.51%)
Streaming Delayed Price Updated: 12:25 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 510,621
Open 5.660
Bid (Size) 5.710 (2,700)
Ask (Size) 5.720 (2,500)
Prev. Close 5.630
Today's Range 5.620 - 5.765
52wk Range 3.381 - 6.510
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1D 
From MannKind
Via GlobeNewswire
News headline image
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus. 
Via Stocktwits

Performance

YTD
+2.1%
+2.1%
1 Month
+1.3%
+1.3%
3 Month
+12.7%
+12.7%
6 Month
+54.5%
+54.5%
1 Year
+2.1%
+2.1%

More News

Read More
News headline image
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
From MannKind
Via GlobeNewswire
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 ↗
Via Stocktwits
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? ↗
Via Stocktwits
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
From Equity Insider
Via GlobeNewswire
News headline image
MannKind Provides Business Updates and 2026 Growth Drivers
From MannKind
Via GlobeNewswire
MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century ↗
Via Stocktwits
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
MannKind Shares FUROSCIX® Business Updates
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at the Jefferies Global Healthcare Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
From MannKind
Via GlobeNewswire
News headline image
MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise ↗
Via Chartmill
Topics Earnings
News headline image
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
From MannKind
Via GlobeNewswire
News headline image
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
From MannKind
Via GlobeNewswire
News headline image
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
From MannKind
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga

Frequently Asked Questions

Is MannKind Corporation - Common Stock publicly traded?
Yes, MannKind Corporation - Common Stock is publicly traded.
What exchange does MannKind Corporation - Common Stock trade on?
MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MannKind Corporation - Common Stock?
The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
What is the current price of MannKind Corporation - Common Stock?
The current price of MannKind Corporation - Common Stock is 5.715
When was MannKind Corporation - Common Stock last traded?
The last trade of MannKind Corporation - Common Stock was at 02/13/26 12:25 PM ET
What is the market capitalization of MannKind Corporation - Common Stock?
The market capitalization of MannKind Corporation - Common Stock is 1.51B
How many shares of MannKind Corporation - Common Stock are outstanding?
MannKind Corporation - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.